Additionally, the 36-month beta value for LSB is 0.57. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for LSB is 3.30M and currently, short sellers hold a 0.24% ratio of that float. The average trading volume of LSB on July 08, 2025 was 19.75K shares.
LSB stock’s latest price update
LakeShore Biopharma Co Ltd (NASDAQ: LSB)’s stock price has soared by 13.72% in relation to previous closing price of $0.98. Nevertheless, the company has seen a gain of 9.31% in its stock price over the last five trading days. prnewswire.com reported 2025-07-08 that BEIJING, July 8, 2025 /PRNewswire/ — LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the “Purchase Agreement”) with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share, at US$0.883 per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of US$1.079 at any time and from time to time during a 36-month period, in a private placement of US$15 million exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. The closing of the private placement is expected to take place as soon as possible upon agreement by the parties to the Purchase Agreement, subject to customary conditions precedent stipulated thereunder.
LSB’s Market Performance
LakeShore Biopharma Co Ltd (LSB) has experienced a 9.31% rise in stock performance for the past week, with a 11.61% rise in the past month, and a -46.57% drop in the past quarter. The volatility ratio for the week is 9.07%, and the volatility levels for the past 30 days are at 7.47% for LSB. The simple moving average for the past 20 days is 13.42% for LSB’s stock, with a -55.42% simple moving average for the past 200 days.
LSB Trading at 4.15% from the 50-Day Moving Average
After a stumble in the market that brought LSB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.03% of loss for the given period.
Volatility was left at 7.47%, however, over the last 30 days, the volatility rate increased by 9.07%, as shares surge +13.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.04% lower at present.
During the last 5 trading sessions, LSB rose by +10.78%, which changed the moving average for the period of 200-days by -78.32% in comparison to the 20-day moving average, which settled at $0.9839. In addition, LakeShore Biopharma Co Ltd saw -82.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of LakeShore Biopharma Co Ltd, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for LSB
Current profitability levels for the company are sitting at:
- -0.87% for the present operating margin
- 0.55% for the gross margin
The net margin for LakeShore Biopharma Co Ltd stands at -0.86%. The total capital return value is set at -0.37%.
The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is -8.29.
Currently, EBITDA for the company is -368.66 million with net debt to EBITDA at -1.15. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The receivables turnover for the company is 0.68for trailing twelve months and the total asset turnover is 0.2.
Conclusion
In conclusion, LakeShore Biopharma Co Ltd (LSB) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
